GF 15
目录号 : GC33334
GF15是有效的中心体聚集(centrosomalclustering)抑制剂，可抑制肿瘤细胞的生长。
Cas No.:888042-13-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | Hela cells are treated with GF 15 (0, 0.25, 0.5, 0.75, 1, 1.25 μM) for 24 and/or 48 hours. Cell viability is examined using the MTT assay[1]. |
Animal experiment: | Mice[1]Beige-nude Xid mice are inoculated s.c. in the right flank with 3×106 OPM2 or HT29 cells. When a tumor is measurable, mice are assigned to a GF 15 treatment group (20, 100 mg/kg) or the control group for 0-20 days. Tumor burden is measured every alternating day using an electronic caliper. |
References: [1]. Raab MS, et al. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2012 Oct 15;72(20):5374-85. | |
GF 15 is a potent inhibitor of centrosomal clustering in tumor cells.
GF 15 leads to multipolar mitosis induction with an EC50 of 900 nM. GF 15 exhibits potent cytotoxicity in a concentration-dependent manner against a broad spectrum of tumor cell types including colon, cervix, glioblastoma, pancreas, leukemia, and myeloma-derived cell lines with IC50s of 1-5 μM[1].
Treatment of mouse xenograft models of human colon cancer and multiple myeloma with GF 15 results in tumor growth inhibition and significantly prolonged survival[1].
[1]. Raab MS, et al. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2012 Oct 15;72(20):5374-85.
| Cas No. | 888042-13-5 | SDF | |
| Canonical SMILES | O=C1[C@]2(C(OCC3=CC=CC=C3)=CC(C[C@H]2C)=O)OC4=C(Cl)C(OC)=CC(OC)=C14 | ||
| 分子式 | C23H21ClO6 | 分子量 | 428.86 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3318 mL | 11.6588 mL | 23.3176 mL |
| 5 mM | 0.4664 mL | 2.3318 mL | 4.6635 mL |
| 10 mM | 0.2332 mL | 1.1659 mL | 2.3318 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。